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BACKGROUND: Approximately half of high-grade serous ovarian carcinomas (HGSOCs) demonstrate homologous recombination repair 
(HR) pathway defects, resulting in a distinct clinical phenotype comprising hypersensitivity to platinum, superior clinical outcome, and 
greater sensitivity to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. EMSY, which is known to be amplified in breast 
and ovarian cancers, encodes a protein reported to bind and inactivate BRCA2. Thus, EMSY overexpression may mimic BRCA2 mutation, 
resulting in HR deficiency. However, to our knowledge, the phenotypic consequences of EMSY overexpression in HGSOC patients has not 
been explored. METHODS: Here we investigate the impact of EMSY expression on clinical outcome and sensitivity to platinum-based 
chemotherapy using available data from transcriptomically characterized HGSOC cohorts. RESULTS: High EMSY expression was associ-
ated with better clinical outcome in a cohort of 265 patients with HGSOC from Edinburgh (overall survival multivariable hazard ratio, 0.58 
[95% CI, 0.38-0.88; P = .011] and progression-free survival multivariable hazard ratio, 0.62 [95% CI, 0.40-0.96; P = .030]). Superior out-
come also was demonstrated in the Medical Research Council ICON7 clinical trial and multiple publicly available data sets. Patients within 
the Edinburgh cohort who had high EMSY expression were found to demonstrate greater rates of complete response to multiple plati-
num-containing chemotherapy regimens (radiological complete response rate of 44.4% vs 12.5% at second exposure; P = .035) and cor-
responding prolonged time to disease progression (median, 151.5 days vs 60.5 days after third platinum exposure; P = .004). 
CONCLUSIONS: Patients with HGSOCs demonstrating high EMSY expression appear to experience prolonged survival and greater plati-
num sensitivity, reminiscent of BRCA-mutant cases. These data are consistent with the notion that EMSY overexpression may render 
HGSOCs HR deficient. Cancer 2019;0:1-10. © 2019 University of Edinburgh. Cancer published by Wiley Periodicals, Inc. on behalf of 
American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits 
use, distribution and reproduction in any medium, provided the original work is properly cited. 
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INTRODUCTION
Ovarian cancer is the most lethal gynecological malignancy, accounting for >14,000 deaths per year in the United States 
alone.1 High-grade serous ovarian carcinoma (HGSOC) accounts for approximately 75% of cases, and is diagnosed at 
an advanced stage in the vast majority of patients.2,3 Although HGSOC is typically sensitive to platinum-based chemo-
therapy at the time of diagnosis, the majority of patients will experience disease recurrence, which accrues resistance to 
platinum resulting in sequentially shorter treatment-free intervals before patients eventually succumb to disease.4
Over the last decade, a wealth of molecular data have been produced in an effort to better characterize HGSOC 
and to identify molecular subtypes of disease with biology that may be exploited therapeutically.5-7 However, 
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currently only sequencing to detect mutations in the 
homologous recombination (HR) DNA repair genes 
BRCA1 and BRCA2 (BRCA) is routinely used to iden-
tify molecular subgroups that are clinically actionable. 
BRCA-mutant patients experience prolonged survival, 
enhanced sensitivity to platinum even with multiple 
exposures, and a greater sensitivity to poly(adenosine 
diphosphate-ribose) polymerase (PARP) inhibition by 
virtue of HR deficiency.8-13
The EMSY gene, also known as C11orf30, encodes 
a nuclear protein that has been identified to bind and 
inactivate BRCA2 and is reportedly amplified in approx-
imately 6% to 18% of HGSOC cases and 7% to 13% of 
sporadic breast cancer cases.5,14,15 EMSY colocalizes to 
sites of DNA damage, and overexpression of a truncated 
form of EMSY able to bind BRCA2 has been reported to 
induce genomic instability and sensitivity to the DNA-
damaging agent mitomycin C.14,16 Overexpression 
of EMSY disrupts the BRCA2/RAD51 pathway after 
DNA damage and may override the HR players RPA 
and PALB2, which bind BRCA2 in the same region as 
EMSY.17 Thus, tumors with EMSY amplification may 
mimic those demonstrating mutational inactivation of 
BRCA2. Similar to BRCA mutation, EMSY amplifica-
tion has been associated with poor prognosis in patients 
with breast cancer and is most common in the HGS his-
tological subtype of OC.14,15,18-22
However, to our knowledge, no association between 
EMSY expression and clinical outcome in patients with 
HGSOC has been made to date. In the current study, we 
sought to perform in silico analysis of available transcrip-
tomic data to investigate whether patients with HGSOCs 
demonstrating high expression of EMSY experience dif-
ferential clinical outcome or sensitivity to platinum-based 
chemotherapy.
MATERIALS AND METHODS
Cohort Descriptions
The Edinburgh cohort comprised 265 HGSOC  patients 
who were treated within the Edinburgh Cancer Centre 
between 1984 and 2006 and identified as part of a pre-
vious study of HGSOC.23 All patients received plati-
num-containing first-line chemotherapy subsequent to 
primary surgical debulking. The distribution of patient 
age at the time of diagnosis, extent of residual disease 
after primary debulking surgery, and International 
Federation of Gynecology and Obstetrics (FIGO) stage 
at the time of diagnosis are detailed in Table 1. The 
Medical Research Council (MRC) ICON7 cohort com-
prised 367 patients with HGSOC from the ICON7 clini-
cal trial, 185 of whom received combination therapy with 
carboplatin and paclitaxel with bevacizumab and 182 of 
whom received the combination of carboplatin and pacli-
taxel alone. These specimens were from patients consent-
ing to the translational research component of the study, 
and were collected across several international sites.
Edinburgh and MRC ICON7 Cohort Gene 
Expression Data
Gene expression data for the Edinburgh and MRC ICON7 
study cohorts were generated as part of a previous study iden-
tifying transcriptomically-defined molecular subtypes of 
HGSOC.23 Briefly, for each cohort, RNA was extracted from 
macrodissected,  formalin-fixed, paraffin-embedded tumor 
TABLE 1. Demographics of HGSOC Patients With High and Low EMSY Expression in the Edinburgh Cohort
Demographics
Low EMSY Expression High EMSY Expression
PNo. % No. %
HGSOC Patients 228 37
FIGO stage of disease at time of diagnosis I 13 5.9% 1 2.8% NSa 
II 15 6.8% 5 13.9%
III 153 68.9% 22 61.1%
IV 41 18.5% 8 22.2%
NA 6 1
Residual disease after debulking surgery <2 cmb 81 40.5% 17 48.6% NSc 
2-5 cm 51 25.5% 8 22.9%
>5 cm 68 34.0% 10 28.6%
NA 28 2
Median age at diagnosis, years 61 (range, 32-86) 61 (range, 43-81) NSd 
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HGSOC, high-grade serous ovarian carcinoma; NA, not available; NS, not 
significant.
aDetermined by Fisher’s exact test: early-stage (stage I-II) versus late-stage (stage III-IV) disease at the time of diagnosis.
bDue to the retrospective nature of these data and the historical classification of optimal surgical resection as <2 cm residual disease in older cases, optimal 
surgical success could not be resolved beyond <2 cm within the Edinburgh cohort.
cDetermined by the chi-square test: <2 cm versus ≥2 cm.
dDetermined by the Student t test.
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material (High Pure kit; Roche Life Science, Indianapolis, 
Indiana), cDNA amplification was performed (FFPE WTA 
System V2; NuGEN, Leek, the Netherlands), and fragmen-
tation and labeling was performed (NuGENEncore Biotin 
Module) followed by hybridization to the Ovarian DSA 
cDNA microarray platform (Almac Diagnostics, Craigavon, 
United Kingdom). Each  cohort was preprocessed using 
the Robust Multi-Array Average (RMA)24 method prior 
to a comprehensive quality control analysis, including 
assessments of sample quality via the Affymetrix percent-
age present metric (Affymetrix, Santa Clara, California)25 
and  cohort metrics using principal components analysis and 
Kolmogorov-Smirnov distributions analysis. Probe sets that 
were informative for EMSY gene expression were extracted 
and per-sample EMSY expression was calculated as the mean 
expression between probe sets (see Supporting Table S1 and 
Table S2) (see Supporting Fig. S1).
Identification of the Threshold for High EMSY 
Expression Within the Edinburgh Cohort
The optimal threshold for dichotomization of the 
Edinburgh cohort into high and low EMSY expression was 
identified using cutpoint analysis of univariable survival 
(see Supporting Fig. S2). This approach identified 14% as 
the optimal threshold, which was subsequently validated by 
application to independent transcriptomic data sets.
Publicly Available Gene Expression Data Sets
Gene expression data from the studies by Pils et al,26 
Tothill et al,7 Mateescu et al,27 and The Cancer Genome 
Atlas (TCGA)5 were accessed using the curatedOvari-
anData R package.28 EMSY gene expression data were 
extracted for samples of serous histology within their 
 respective studies. Samples documented as serous grade 
1 were excluded as possible low-grade SOC.
Survival Data
Clinical annotation for the Edinburgh cohort was 
 retrieved from the Edinburgh Ovarian Cancer Database, 
in which data are entered prospectively in an unselected 
manner by a single individual as part of routine care. 
Survival data for the Pils et al,26 Tothill et al,7 Mateescu 
et al,27 and TCGA5 data sets were accessed using the 
 curatedOvarianData R package.28
Platinum Response Data
Detailed response data to each cytotoxic therapy regi-
men for patients in the Edinburgh cohort were collected 
retrospectively from the Edinburgh Ovarian Cancer 
Database in conjunction with archived patient notes. 
Radiological responses were reported as per World 
Health Organization or Response Evaluation Criteria in 
Solid Tumors (RECIST) criteria, with the exception of 
the need for confirmatory scans. CA 125 tumor marker 
responses were reported according to Gynecological 
Cancer InterGroup (GCIG) guidelines.29
Statistical Analyses
Statistical analyses were performed using R (version 3.5.1; 
R Foundation, Vienna, Austria). Survival analyses were 
conducted using Cox proportional hazards models for 
progression-free survival (PFS) and overall survival (OS). 
Survival differences were visualized using the Kaplan-Meier 
method. Multivariable survival analyses accounted for the 
success of primary surgical debulking, FIGO stage at the 
time of diagnosis, and patient age at the time of diagnosis, 
with the exception of the Mateescu et al data set, in which 
data regarding surgical debulking and  patient age were not 
available. Within the MRC ICON7 data set, chemotherapy 
regimen (bevacizumab treatment vs placebo) was also ac-
counted for in multivariable analyses where patients from 
both treatment arms were analyzed together. Survival dif-
ferences are presented as univariable or multivariable hazard 
ratios (uniHR or multiHR) alongside their corresponding 
95% CIs and P values. Comparisons of categorical variables 
were performed using the chi-square or Fisher’s exact tests 
as appropriate. Differences in time to disease progression 
from receipt of platinum were evaluated using the Mann-
Whitney U test. Adjustments for multiple testing were 
made using the Bonferroni correction when specified.
RESULTS
High EMSY Expression Was Associated With 
Superior Survival in the Edinburgh HGSOC 
Cohort
Gene expression data for 265 HGSOCs in the Edinburgh 
cohort were probed for EMSY expression. 14% of 
HGSOC patients with the highest levels of EMSY ex-
pression (high-EMSY) demonstrated prolonged OS 
compared with the remainder of the cohort (low-EMSY) 
(uniHR, 0.63 [95% CI, 0.43-0.93; P = .020]) (Fig. 1A) 
(Table 2).5,7,26,27 A multivariable model accounting for 
FIGO stage at  diagnosis, residual disease after primary de-
bulking surgery, and patient age demonstrated an OS ben-
efit for patients within the high-EMSY group (multiHR, 
0.58 [95% CI, 0.38-0.88; P = .011]) (see Supporting 
Table S3.1). A multivariable model also demonstrated 
that the high-EMSY group had prolonged PFS versus the 
low-EMSY group (multiHR, 0.62 [95% CI, 0.40-0.96; 
P = .030]) (Fig. 1B) (see Supporting Table S3.2).
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Impact of High EMSY Expression Within  
the MRC ICON7 Cohort
To validate the association between superior clini-
cal outcome and high EMSY expression, the gene ex-
pression cutoff value from the Edinburgh data set was 
 applied directly to the MRC ICON7 cohort character-
ized on the same gene expression platform.23 Patients in 
the high-EMSY group within this cohort demonstrated 
prolonged OS when accounting for FIGO stage at diag-
nosis, residual disease after primary debulking surgery, 
trial arm (bevacizumab-treated patients vs control arm), 
and age at diagnosis (multiHR, 0.46 [95% CI, 0.23-0.91; 
P = .025]) (Fig. 1C) (see Supporting Table S3.3), but did 
not demonstrate superior PFS (multiHR, 0.89 [95% CI, 
0.57-1.38; P = .599]) (see Supporting Fig. S3).
Despite severely limited power, analysis of the high-
EMSY population demonstrated that patients in the 
high-EMSY group within the bevacizumab treatment arm 
(14 patients) had inferior survival compared with those 
patients who received chemotherapy alone (10 patients) 
(multiHR, 11.78 [95% CI, 1.31-106.32; P = .027]) (Fig. 1D) 
(see Supporting Table S3.4). Within the control arm spe-
cifically, patients in the high-EMSY group demonstrated 
markedly superior OS compared with patients in the 
low-EMSY group (multiHR, 0.12 [95% CI, 0.02-0.083; 
P = .032) (see Supporting Table S3.5).
Validation of Superior Outcomes in Patients 
With HGSOCs With High EMSY Expression
To further validate the association between high EMSY 
expression and superior clinical outcome, publicly 
available gene expression data sets were accessed using 
the curatedOvarianData package.28 These data sets 
were characterized on a variety of platforms, thereby 
Figure 1. Clinical outcome in patients with high-grade serous ovarian carcinomas (HGSOCs) demonstrating high EMSY 
expression. (A) Overall survival (OS) in the Edinburgh cohort. (B) Progression-free survival (PFS) in the Edinburgh cohort. 
(C) OS in the Medical Research Council (MRC) ICON7 clinical trial cohort. (D) OS in the MRC ICON7 clinical trial cohort stratified 
by trial arm. multiHR indicates multivariable hazard ratio; uniHR, univariable hazard ratio.
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preventing direct application of the cutoff value from 
the Edinburgh cohort. Therefore, the use of thresholds 
at the 14th percentile of EMSY expression within each 
data set was proposed. The validity of this approach was 
 assessed using the MRC ICON7 control cohort arm and, 
consistent with results using the absolute threshold de-
rived from the Edinburgh cohort, analysis of the 14% 
of HGSOCs with the highest EMSY expression demon-
strated prolonged OS (multiHR, 0.23 [95% CI, 0.07-
0.72; P = .012]) (see Supporting Fig. S4).
EMSY expression data were extracted for data sets 
from studies by Tothill et al,7 Pils et al,26 Mateescu et al,27 
and TCGA.5 Superior OS for patients in the high-EMSY 
group was demonstrated in the cohorts from the Pils 
et al26 (multiHR, 0.27 [95% CI, 0.08-0.87; P = .028]) 
(Fig. 2A) (see Supporting Table S3.6) and Mateescu et al27 
(multiHR, 0.43 [95% CI, 0.18-0.99; P = .048]) 
(Fig. 2C) (see Supporting Table S3.7) studies. The  cohort 
from the study by Pils et al demonstrated superior PFS 
within the high-EMSY population (multiHR, 0.52 [95% 
CI, 0.29-0.92; P = .026]) (Fig. 2B) (see Supporting 
Table S3.8).26 The corresponding PFS difference in the 
Mateescu et al27 cohort was not found to be statistically 
significant (uniHR, 0.51 [95% CI, 0.24-1.09; P = .084]; 
and multiHR, 0.59 [95% CI, 0.27-1.25; P = .168]) 
(Fig. 2D) (see Supporting Table S3.9). Notably, data 
 regarding residual disease after primary debulking surgery 
were not available for the Mateescu et al27 study  cohort, 
thereby precluding the ability to account for this variable.
Prolonged OS was demonstrated in high-EMSY 
patients from the study by Tothill et al7 at the univari-
able level (uniHR, 0.50 [95% CI, 0.27-0.93; P = .029]) 
(Fig. 2E), but did not reach statistical significance in a 
multivariable model accounting for patient age, FIGO 
stage at diagnosis, and residual disease after debulking 
surgery (multiHR, 0.60 [95% CI, 0.32-1.13; P = .112]) 
(see Supporting Table S3.10). The apparent prolonged 
PFS noted on multivariable analysis in patients in the 
high-EMSY group in the cohort of patients from the 
study by Tothill et al7 did not cross the threshold for sta-
tistical significance (multiHR, 0.63 [95% CI, 0.39-1.04; 
P = .072]) (Fig. 2F) (see Supporting Table S3.11).
The TCGA cohort5 did not demonstrate signifi-
cantly prolonged PFS within the high-EMSY group 
(uniHR, 0.74 [95% CI, 0.50-1.09; P = .122]) (see 
Supporting Fig. S5). PFS analysis restricted to patients 
diagnosed at an advanced stage of disease demonstrated 
prolonged PFS in this subset (uniHR, 0.62 [95% CI, 
0.41-0.94; Bonferroni-adjusted P = .046]) (Fig. 2H) 
(see Supporting Table S3.12). High EMSY expression 
was not found to be associated with superior OS within 
the TCGA cohort5 (uniHR, 0.95 [95% CI, 0.68-1.35]) 
(Fig. 2G).
Impact of Sampling Site on the Identification 
of the High-EMSY Subgroup With a Superior 
Clinical Outcome
Data regarding the sampling site of arrayed specimens 
were available for the cohort from the study by Tothill et al.7 
Patients in the high-EMSY group with sampling of the 
primary adnexal mass (ovary or fallopian tube) were 
found to demonstrate significantly superior OS (mul-
tiHR for OS, 0.28 [95% CI, 0.09-0.90; P = .032]; and 
multiHR for PFS, 0.55 [95% CI, 0.28-1.10; P = .091]) 
(see Supporting Figs S6A and S6C), whereas those from 
other sampling sites demonstrated no apparent survival 
TABLE 2. Univariable and Multivariable Analyses of Clinical Outcome in Patients With HGSOCs 
Demonstrating High EMSY Expression across Multiple Data Sets
Data Set Event Type
High EMSY 
Expression No. 
of Cases
Low EMSY 
Expression No. 
of Cases
Univariable Multivariable
HR 95% CI P HR 95% CI P
Edinburgh OS 37 228 0.63 0.43-0.93 .020 0.58 0.38-0.88 .011
PFS 0.67 0.45-1.00 .052 0.62 0.40-0.96 .030
MRC ICON7 cohort OS 24 343 0.68 0.35-1.32 .254 0.46 0.23-0.91 .025
PFS 1.27 0.82-1.97 .280 0.89 0.57-1.38 .599
Pils et al26 cohort OS 24 146 0.31 0.10-1.02 .053 0.27 0.08-0.87 .028
PFS 0.70 0.41-1.22 .210 0.52 0.29-0.92 .026
Mateescu et al27cohort OS 11 64 0.40 0.17-0.94 .035 0.43 0.18-0.99 .048
PFS 0.51 0.24-1.09 .084 0.59 0.27-1.25 .168
Tothill et al7 cohort OS 35 210 0.50 0.27-0.93 .029 0.60 0.32-1.13 .112
PFS 0.70 0.44-1.09 .114 0.63 0.39-1.04 .072
TCGA5 cohort OS 77 472 0.95 0.68-1.34 .789 1.18 0.83-1.66 .358
TCGA stage III/IV PFS 71 435 0.62 0.41-0.94 .046a 0.68 0.45-1.04 .076
Abbreviations: HGSOC, high-grade serous ovarian carcinoma; HR, hazard ratio; MRC, Medical Research Council; OS, overall survival; PFS, progression-free 
survival; TCGA, The Cancer Genome Atlas.
aBonferroni-adjusted P value.
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benefit (multiHR for OS, 0.85 [95% CI, 0.37-1.97; 
P = .710]; and multiHR for PFS, 0.91 [95% CI, 0.43-
1.89; P = .794]) (see Supporting Figs. S6B and S6D). 
The vast majority of samples from the Edinburgh and 
MRC ICON7 data sets were derived from primary ad-
nexal masses and the sampling site data were not available 
for the data sets from the studies by Pils et al,26 Mateescu 
et al,27 and TCGA,5 thereby precluding investigation of 
the potential impact of extra-adnexal sampling in these 
data sets.
High EMSY Expression Was Associated With 
Greater Platinum Sensitivity  
in the Edinburgh Cohort
Detailed response data regarding cytotoxic therapy regi-
mens were collected for the Edinburgh cohort. Patients 
in the high-EMSY group demonstrated a superior radio-
logical complete response rate at the time of second plati-
num exposure (44.4% [4 of 9 patients] vs 12.5% [8 of 
64 patients]; Fisher’s exact P = .035) (Fig. 3A). Similarly, 
patients in the high-EMSY group were found to have su-
perior rates of complete CA 125 tumor marker response 
at the time of first (88.0% [22 of 25 patients] vs 55.0% 
[82 of 149 patients]; P = .002) and second (53.3% [8 of 
15 patients] vs 21.3% [17 of 80 patients]; P = .021) plati-
num exposure. At the time of fourth platinum exposure, 
patients in the high-EMSY group demonstrated a sig-
nificantly greater objective CA 125 response rate (100% 
[3 of 3 patients] vs 0% [0 of 4 patients]; Fisher’s exact 
P = .029) (see Supporting Fig. S7). Response data strati-
fied by type of platinum-containing regimen are detailed 
in Supporting Table S4.
The median time to first (radiological or CA 125 
tumor marker) disease progression after second plat-
inum exposure was 127 days in the high-EMSY group 
compared with 83.5 days in the low-EMSY group, but 
this did not reach statistical significance (P = .084) 
(Fig. 3B). Patients in the high-EMSY group demon-
strated a significantly longer time to first disease progres-
sion after third platinum exposure (median, 151.5 days vs 
60.5 days; P = .004), which was significant when consid-
ering only progression by radiology (median, 231 days vs 
50 days; P = .003) and CA 125 tumor marker (median, 
151.5 days vs 94 days; P = .041) specifically.
High EMSY Expression Was Associated  
With Superior Outcome in Patients With  
High-Risk HGSOC
Patients with advanced stage (FIGO stage III/IV) 
HGSOC with gross macroscopic residual disease after 
debulking surgery have particularly poor prognosis 
(“high-risk” patients).30 Within the Edinburgh cohort, 
a greater percentage of patients in the high-EMSY group 
remained alive without disease recurrence within the 
context of high-risk disease at 2 years (25.0% [4 of 16 
patients] vs 9.2% [10 of 109 patients]; P = .081), 3 years 
(18.8% [3 of 16 patients] vs 3.6% [4 of 110 patients]; 
P = .043), 5 years (17.6% [3 of 17 patients] vs 2.7% 
[3 of 111 patients]; P = .031), and 10 years (12.5% [2 of 
16 patients] vs 0.9% [1 of 112 patients]; P = .041) from 
diagnosis (see Supporting Fig. S8A), suggesting that 
high-risk patients with high EMSY expression are more 
likely to achieve favorable long-term clinical outcome.
A similar effect was observed within the cohort 
from the study by Pils et al26 at 12 months (100% 
[9 of 9 patients] vs 61.5% [24 of 39 patients]; P = .041), 
18 months (88.9% [8 of 9 patients] vs 17.6% [6 of 34 
patients]; P < .001), and 2 years (50.0% [4 of 8 patients] 
vs 3.1% [1 of 32 patients]; P = .004) (see Supporting Fig. 
S8B). Although similar trends were observed in the high-
risk patients with adnexal specimens from the study by 
Tothill et al7 at 12 months from diagnosis, these did not 
approach statistical significance (100% [5 of 5 patients] 
vs 62.5% [20 of32 patients]; P = .152) (see Supporting 
Fig. S9). However, patients with late-stage disease in the 
Tothill et al7 study cohort (irrespective of residual disease 
after debulking surgery) demonstrated the same effect 
at 12 months (95% [19 of 20 patients] vs 67.8% [78 of 
115 patients]; P = .014) and 18 months (70% [14 of 20 
patients] vs 42.3% [47 of 111 patients]; P = .029) from 
diagnosis (see Supporting Fig. S8C).
DISCUSSION
Approximately one-half of HGSOCs are described as 
having identifiable defects in the HR pathway, with the 
archetypal defects being germline or somatic BRCA in-
activation.3 Surprisingly, the EMSY gene, the product of 
which has been shown to bind and inactivate BRCA2, 
has received relatively little attention in HGSOC, despite 
Figure 2. Clinical outcome of patients with high-grade serous ovarian carcinomas (HGSOCs) demonstrating high EMSY 
expression across multiple data sets. (A) Overall survival (OS) within the Pils et al cohort.26 (B) Progression-free survival (PFS) 
within the Pils et al cohort.26 (C) OS within the Mateescu et al cohort.27 (D) PFS within the Mateescu et al cohort.27 (E) OS within 
the Tothill et al cohort.7 (F) PFS within the Tothill et al cohort.7 (G) OS within The Cancer Genome Atlas (TCGA) cohort5 and 
(H) PFS of patients with advanced stage disease within the TCGA cohort.5 multiHR indicates multivariable hazard ratio; uniHR, 
univariable hazard ratio.
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being associated with a poor prognosis in individuals 
with breast cancer.14,15,18-22
Amplification of 11q13 has been identified as a 
common event in patients with breast cancer and OC, 
and previous investigations have pointed toward EMSY 
as the critical gene in this amplicon.14,15,22 To our knowl-
edge, only a single study to date has reported on 11q13 
amplification and prognosis in patients with OC, and 
reported no survival difference in patients with SOC 
upon multivariable analysis,21 with other studies not in-
vestigating the impact on patient outcome.5,15 Notably, 
this study did not distinguish HGSOC from low-grade 
SOC, which now is recognized as a distinct clinical and 
molecular disease entity.31-33 Moreover, given the mixed 
reports of correlation strength  between EMSY copy num-
ber and expression,14,15,34 investigation of the association 
between EMSY expression and survival may prove more 
fruitful than associations with copy number alone.
Through in silico analysis of local and publicly 
available transcriptomic data, we identify a subgroup of 
HGSOCs defined by high levels of EMSY expression. 
The threshold for EMSY overexpression was defined 
within the Edinburgh cohort and validated directly 
within the MRC ICON7 cohort characterized on the 
same platform. To identify the high-EMSY population 
within independent cohorts characterized by hetero-
geneous methodologies, we used a percentile-based 
expression threshold after validating this approach in 
the MRC ICON7 cohort. Although a significant dif-
ference in outcome within the TCGA cohort was evi-
dent only upon exploratory analysis limited to patients 
with advanced stage disease at the time of diagnosis, 
multivariable analysis restricted to patients with late-
stage disease in the other evaluable cohorts confirmed 
prolonged survival in their respective populations (data 
not shown).
Figure 3. Platinum sensitivity of patients with high-grade serous ovarian carcinomas (HGSOCs) with high EMSY expression within 
the Edinburgh cohort. (A) Rate of complete radiological and CA 125 tumor marker response to platinum-containing chemotherapy. 
(B) Time to radiological, CA 125, and earliest disease progression from receipt of platinum-containing chemotherapy.
A
B
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Similar to BRCA-mutant HGSOC, high-EMSY 
HGSOCs appear to demonstrate prolonged survival across 
multiple independent data sets, and demonstrate a greater 
benefit from platinum-based chemotherapy than their 
low-EMSY counterparts. Patients in the high-EMSY group 
within the Edinburgh cohort demonstrated a >3-fold 
radiological complete response rate to second platinum 
exposure compared with patients in the low-EMSY group.
Intriguingly, within the MRC ICON7 cohort, we 
demonstrated that the benefit conferred by high EMSY 
expression may be abrogated upon addition of the an-
tiangiogenic agent bevacizumab to first-line therapy, 
although the power of these analyses was severely lim-
ited. Clearly, overinterpretation of these data must be 
avoided in light of the low numbers of patients in the 
high-EMSY group between the two treatment arms, and 
the presented analyses do not fulfil the REporting rec-
ommendations for tumor MARKer prognostic studies 
(REMARK) criteria for biomarker studies.35 However, 
these data do suggest that analysis of the differential im-
pact of bevacizumab treatment between HR-intact and 
HR-deficient HGSOCs may now be warranted. Robust 
evaluation of the impact of HR status on bevacizumab 
efficacy has the potential to better define those patients 
who are most likely to derive benefit from the addition of 
antiangiogenic agents to first-line care. These data will be 
of particular interest in light of ongoing trials combining 
antiangiogenics with PARP inhibitors.36
Advanced stage of disease at the time of diagnosis 
and suboptimal surgical resection both are associated with 
markedly inferior survival in patients with HGSOC.30 
Patients with both of these features represent those 
with particularly high-risk disease. We observed that 
within these high-risk patients, those with high EMSY 
expression have a greater chance of remaining free of dis-
ease recurrence (12.5% vs <1% at 10 years from diagnosis 
within the Edinburgh cohort), suggesting that patients 
in the high-EMSY group could represent a group with 
favorable long-term clinical outcome even in the face of 
otherwise poor prognostic markers.
Within the data set from the study by Tothill et al,7 
we observed that although high EMSY expression was as-
sociated with prolonged survival, this phenomenon was 
not apparent in patients in whom expression data were 
generated using samples that were not taken from the pri-
mary adnexal mass. There are several plausible explana-
tions for this observation. First, differences in the tumor 
microenvironment at different anatomic sites may well 
have impacted EMSY expression. Second, the contam-
ination of tumor samples with different nonmalignant 
cell types has the potential to alter bulk EMSY expres-
sion. Third, intratumor heterogeneity as a result of 
tumor evolution may have resulted in differential tumor 
cell EMSY expression between the primary tumor mass 
and more distant disease sites. In any respect, differ-
ential gene expression between sampling sites has clear 
implications for the identification of pertinent molecu-
lar events in both the clinical and research setting. In 
particular, the frequency of extra-adnexal sampling may 
account for weakened trends between EMSY expression 
and clinical outcome in some data sets. Transcriptomic 
characterization of the Edinburgh23 and MRC ICON7 
cohorts was performed on specimens that were nearly 
exclusively taken from the primary adnexal mass, and in 
both of these data sets samples were macrodissected prior 
to RNA extraction to minimize stromal contamination. 
Both these cohorts demonstrated a marked OS benefit in 
patients in the high-EMSY group.
These data demonstrate the power of in silico anal-
ysis of preexisting data sets to identify novel, clinically 
meaningful subtypes of disease. Collectively, the current 
study findings allude to a subgroup of HGSOC patients 
defined by high levels of EMSY expression who appear to 
demonstrate improved clinical outcome and greater sen-
sitivity to platinum-based chemotherapy, consistent with 
the notion that EMSY overexpression renders HGSOCs 
HR deficient. Given the role of EMSY in disrupting the 
BRCA2/RAD51 HR pathway demonstrated by previous 
studies14,16,17 and the apparent BRCA-like clinical pheno-
type described here in patients with high-EMSY HGSOC, 
investigation of the sensitivity of EMSY-overexpressing 
tumors to PARP inhibition has the potential to improve 
our understanding of which patients benefit the most 
from these agents. The correlation of EMSY expression 
with existing HR deficiency signatures and scores should 
also be explored. Moreover, the impact of differential 
EMSY expression in other disease settings, most notably 
breast and prostate cancer, should now be investigated.
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